Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers - Results of a large scale microarray analysis

European Journal of Cancer

Volumn 45, Issue 3, 2009, Pages 405-413

  Rody, Achim ^a   Karn, Thomas ^a   Ruckhäberle, Eugen ^a   Hanker, Lars ^a   Metzler, Dirk ^a   Müller, Volkmar ^b   Solbach, Christine ^a   Ahr, Andre ^a   Gätje, Regine ^a   Holtrich, Uwe ^a   Kaufmann, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Breast cancer; Microarray; Plexin; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PLEXIN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECURRENCE RISK; TUMOR VOLUME;

BREAST NEOPLASMS; CELL ADHESION MOLECULES; DISEASE-FREE SURVIVAL; ESTROGENS; FEMALE; HUMANS; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RNA, MESSENGER;

EID: 59149105217     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.10.016     Document Type: Article

References (41)

1. Kruger R.P., Aurandt J., and Guan K.L. Semaphorins command cells to move. Nat Rev Mol Cell Biol 6 10 (2005) 789-800
2. Bussolino F., Valdembri D., Caccavari F., and Serini G. Semaphoring vascular morphogenesis. Endothelium 13 2 (2006) 81-91
3. Giordano S., Corso S., Conrotto P., et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 4 9 (2002) 720-724
4. Behar O., Golden J.A., Mashimo H., Schoen F.J., and Fishman M.C. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 383 (1996) 525-528
5. Gitler A.D., Lu M.M., and Epstein J.A. PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. Dev Cell 7 (2004) 107-116
6. Torres-Vazquez J., Gitler A.D., Fraser S.D., et al. Semaphorin-Plexin signaling guides patterning of the developing vasculature. Dev Cell 7 1 (2004) 117-123
7. Kagoshima M., and Ito T. Diverse gene expression and function of semaphorins in developing lung: positive and negative regulatory roles of semaphorins in lung branching morphogenesis. Genes Cells 6 (2001) 559-571
8. Morris J.S., Stein T., Pringle M.A., et al. Involvement of axonal guidance proteins and their signaling partners in the developing mouse mammary gland. J Cell Physiol 206 1 (2006) 16-24
9. Takegahara N., Takamatsu H., Toyofuku T., et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat Cell Biol 8 6 (2006) 615-622
10. Tse C., Xiang R.H., Bracht T., and Naylor S.L. Human semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. Cancer Res 62 2 (2002) 542-546
11. Xiang R., Davalos A.R., Hensel C.H., et al. Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res 62 9 (2002) 2637-2643
12. Brambilla E., Constantin B., Drabkin H., and Roche J. Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. Am J Pathol 156 3 (2000) 939-950
13. Swiercz J.M., Kuner R., and Offermanns S. Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2. J Cell Biol 165 (2004) 869-880
14. Rody A., Holtrich U., Gaetje R., et al. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of Plexin B1. Clin Cancer Res 13 4 (2007) 1115-1122
15. Rody A., Karn T., Holtrich U., and Kaufmann M. "Stem cell like" breast cancers - a model for the identification of new prognostic/predictive markers in endocrine responsive breast cancer exemplified by Plexin B1. Eur J Obst Gynecol Reprod Biol 139 1 (2008) 11-15
16. Ruckhäberle E, Rody A, Engels K, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2007;December 4.
17. Rody A, Holtrich U, Muller V, et al. c-Kit: identification of co-regulated genes by gene expression profiling and clinical relevance of two breast cancer subtypes with stem cell like features. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24:622.
18. Ahr A., Karn T., Solbach C., et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359 9301 (2002) 131-132
19. Pawitan Y., Bjohle J., Amler L., et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7 6 (2005) R953-R964
20. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 4 (2006) 262-272
21. Loi S., Haibe-Kains B., Desmedt C., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25 10 (2007) 1239-1246
22. Minn A.J., Gupta G.P., Siegel P.M., et al. Genes that mediate breast cancer metastasis to lung. Nature 436 7050 (2005) 518-524
23. Desmedt C., Piette F., Loi S., et al. TRANSBIG Consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13 11 (2007) 3207-3214
24. The International Genomics Consortium (IGC). The expO project (Expression Project For Oncology). .
25. Li C., and Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 98 1 (2001) 31-36
26. Irizarry R.A., Bolstad B.M., Collin F., et al. Summaries of Affymetrix GeneChip probe level data. Nucl Acids Res 31 4 (2003) e15
27. Foekens J.A., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24 11 (2006) 1665-1671
28. Gong Y., Yan K., Lin F., et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8 3 (2007) 203-211
29. Bonnefoi H., Potti A., Delorenzi M., et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8 12 (2007) 1071-1078
30. Alexe G., Dalgin G.S., Scanfeld D., et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 67 22 (2007) 10669-10676
31. Venables WN, Ripley BD. Modern applied statistics with S (4th ed.). Springer; 2002. ISBN 0-387-95457-0.
32. de Azambuja E., Cardoso F., de Castro Jr. G., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Brit J Cancer 96 10 (2007) 1504-1513
33. Spyratos F., Ferrero-Poüs M., Trassard M., et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 94 8 (2002) 2151-2159
34. Ivshina A.V., George J., Senko O., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66 21 (2006) 10292-102301
35. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 9460 (2005) 671-679
36. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 19 (2001) 10869-10874
37. Calza S., Hall P., Auer G., et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8 4 (2006) R34
38. Wirapati P., Sotiriou C., Kunkel S., et al. Meta-analysis of gene-expression profiles in breast cancer: toward a unified understanding of breast cancer sub-typing and prognosis signatures. Breast Cancer Res 10 4 (2008) R65
39. Ignatiadis M., and Sotiriou C. Understanding the molecular basis of histologic grade. Pathobiology 75 2 (2008) 104-111
40. Anderson W.F., Chen B.E., Jatoi I., and Rosenberg P.S. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 100 1 (2006) 121-126
41. Jatoi I., Chen B.E., Anderson W.F., and Rosenberg P.S. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25 13 (2007) 1683-1690